Tags

Type your tag names separated by a space and hit enter

FGF23: a key player in mineral and bone disorder in CKD.
Nefrologia. 2009; 29(5):392-6.N

Abstract

FGF23 is a recently identified hormone regulating mineral and vitamin D metabolism. In patients with chronic kidney disease (CKD), circulating FGF23 levels are progressively elevated to compensate for persistent phosphate retention, which result in reduced renal production of 1,25-dihydroxyvitamin D and thereby stimulate secretion of parathyroid hormone, suggesting its critical role in the pathogenesis of altered mineral homeostasis in CKD. Furthermore, it has recently been shown that FGF23 directly acts on parathyroid gland and mediate secretion of parathyroid hormone in the presence of Klotho as a cofactor, although such effects are not yet confirmed in patients with CKD. FGF23 can also be used as a predictor of mortality as well as future development of refractory hyperparathyroidism in patients undergoing dialysis therapy, where FGF23 levels are markedly elevated in response to hyperphosphatemia and active vitamin D treatment. This brief review summarizes recent insights into the role of FGF23 in the pathogenesis of mineral and bone disorders in CKD.

Authors+Show Affiliations

Division of Nephrology and Kidney Center, Kobe University School of Medicine, Kobe, Japan.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

19820750

Citation

Komaba, H, and M Fukagawa. "FGF23: a Key Player in Mineral and Bone Disorder in CKD." Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia, vol. 29, no. 5, 2009, pp. 392-6.
Komaba H, Fukagawa M. FGF23: a key player in mineral and bone disorder in CKD. Nefrologia. 2009;29(5):392-6.
Komaba, H., & Fukagawa, M. (2009). FGF23: a key player in mineral and bone disorder in CKD. Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia, 29(5), 392-6. https://doi.org/10.3265/Nefrologia.2009.29.5.5400.en.full
Komaba H, Fukagawa M. FGF23: a Key Player in Mineral and Bone Disorder in CKD. Nefrologia. 2009;29(5):392-6. PubMed PMID: 19820750.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - FGF23: a key player in mineral and bone disorder in CKD. AU - Komaba,H, AU - Fukagawa,M, PY - 2009/10/13/entrez PY - 2009/10/13/pubmed PY - 2010/1/7/medline SP - 392 EP - 6 JF - Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia JO - Nefrologia VL - 29 IS - 5 N2 - FGF23 is a recently identified hormone regulating mineral and vitamin D metabolism. In patients with chronic kidney disease (CKD), circulating FGF23 levels are progressively elevated to compensate for persistent phosphate retention, which result in reduced renal production of 1,25-dihydroxyvitamin D and thereby stimulate secretion of parathyroid hormone, suggesting its critical role in the pathogenesis of altered mineral homeostasis in CKD. Furthermore, it has recently been shown that FGF23 directly acts on parathyroid gland and mediate secretion of parathyroid hormone in the presence of Klotho as a cofactor, although such effects are not yet confirmed in patients with CKD. FGF23 can also be used as a predictor of mortality as well as future development of refractory hyperparathyroidism in patients undergoing dialysis therapy, where FGF23 levels are markedly elevated in response to hyperphosphatemia and active vitamin D treatment. This brief review summarizes recent insights into the role of FGF23 in the pathogenesis of mineral and bone disorders in CKD. SN - 0211-6995 UR - https://www.unboundmedicine.com/medline/citation/19820750/FGF23:_a_key_player_in_mineral_and_bone_disorder_in_CKD_ L2 - http://www.revistanefrologia.com/es/linksolver/ft/ivp/0211-6995/29/392 DB - PRIME DP - Unbound Medicine ER -